Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
First-line nivolumab plus ipilimumab in unresectable mali... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
0
Authors
Paul Baas
21 more
Paul Baas
•
Arnaud Scherpereel
19 more
•
Gérard Zalcman
Published
January 1, 2021
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet
Topics
Medicine
Cancer Oncology
Dermatology
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s0140-6736(20)32714-8
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet
Topics
Medicine
Cancer Oncology
Dermatology
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s0140-6736(20)32714-8
Other Formats
PDF
